EGFR and neoplasm: In the L-sided tumor group, median PFS and OS were significantly longer in patients treated with anti-EGFR in comparison to patients treated with R/T [median PFS: 7.2 (95% CI 6.5-7.8) vs 3.6 months (95% CI 3.2-3.9), HR 0.43 (95% CI 0.2-0.76), p=0.004; median OS: 14.9 (95% CI 7.2-22.7) vs 10.9 months (95% CI 6.0-15.9), HR 0.52 (95% CI 0.28-0.98), p=0.045].